Post-marketing withdrawal of 462 medicinal products because of adverse drug reactions: a systematic review of the world literature

Abstract

BackgroundThere have been no studies of the patterns of post-marketing withdrawals of medicinal products to which adverse reactions have been attributed. We identified medicinal products that were withdrawn because of adverse drug reactions, examined the evidence to support such withdrawals, and explored the pattern of withdrawals across countries.MethodsWe searched PubMed, Google Scholar, the WHO’s database of drugs, the websites of drug regulatory authorities, and textbooks. We included medicinal products withdrawn between 1950 and 2014 and assessed the levels of evidence used in making withdrawal decisions using the criteria of the Oxford Centre for Evidence Based Medicine.ResultsWe identified 462 medicinal products that were withdrawn from the market between 1953 and 2013, the most common reason being hepatotoxicity. The supporting evidence in 72 % of cases consisted of anecdotal reports. Only 43 (9.34 %) drugs were withdrawn worldwide and 179 (39 %) were withdrawn in one country only. Withdrawal was significantly less likely in Africa than in other continents (Europe, the Americas, Asia, and Australasia and Oceania). The median interval between the first reported adverse reaction and the year of first withdrawal was 6 years (IQR, 1–15) and the interval did not consistently shorten over time.ConclusionThere are discrepancies in the patterns of withdrawal of medicinal products from the market when adverse reactions are suspected, and withdrawals are inconsistent across countries. Greater co-ordination among drug regulatory authorities and increased transparency in reporting suspected adverse drug reactions would help improve current decision-making processes.Electronic supplementary materialThe online version of this article (doi:10.1186/s12916-016-0553-2) contains supplementary material, which is available to authorized users.

Knowledge, attitude and practice toward adverse drug reaction reporting among practicing clinicians at a tertiary care hospital

“…5 Various Studies have shown that 462 medicinal products were withdrawn between 1953-2013 due to ADR reporting. 6 After the launch of the Pharmacovigilance Programme of India (PvPI) in 2010, Indian Pharmacovigilance has progressed tremendously, but a lot more has to be done to make the country truly pharmacovigilant. Under PvPI, Adverse drug reaction Monitoring Centre (AMC) set up in Medical colleges and Multispecialty Hospitals play a major role in collection and follow-up of ADR reports from healthcare professionals.…”

Chitosan-coated diacerein nanosuspensions as a platform for enhancing bioavailability and lowering side effects: preparation, characterization, and ex vivo/in vivo evaluation

“…The removal of such products from the market can result in loss of confidence in medications by the public and loss of effective compounds and loss of profit for drug manufacturers. 1 According to the US Food and Drug Administration (FDA), a drug is usually withdrawn from the market because of safety concerns that cannot be corrected or when its risks overshadow its benefits. Diacerein (DCN) is a drug used for the treatment of osteoarthritis (OA) at a dosage of 50-100 mg daily in two divided doses; it inhibits the synthesis and activity of interleukin 1-β (inflammatory mediator in OA).…”

The Uses of Stem Cells in Toxicology Studies

“…Son yıllarda beklobrat, ketokonazol, nevirapin, nefazodon, sitaksentan sodyum vb etken maddeleri içeren ilaçlar dünyanın farklı bölgelerinde karaciğere bağlı yan etkiler nedeniyle piyasadan çekilmiştir [22].…”